TN2014000318A1 - Synthetic apelin mimetics for the treatment of heart failure - Google Patents

Synthetic apelin mimetics for the treatment of heart failure

Info

Publication number: TN2014000318A1
Authority: TN; Tunisia
Prior art keywords: heart failure; treatment; polypeptides; diabetes; hypertension
Prior art date: 2012-01-27

Application number

TNP2014000318A

Other languages

English (en)

Inventor

Frederic Zecri

Andrei Golosov

Philipp Grosche

Hidetomo Imase

David Thomas Parker

Kayo Yasoshima

Hongjuan Zhao

Qiying Hu

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-01-27

Filing date

2014-07-23

Publication date

2015-12-21

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47997598&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2014000318(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2014-07-23 Application filed by Novartis Ag filed Critical Novartis Ag

2015-12-21 Publication of TN2014000318A1 publication Critical patent/TN2014000318A1/fr

Links

102000018746 Apelin Human genes 0.000 title 1
108010052412 Apelin Proteins 0.000 title 1
206010019280 Heart failures Diseases 0.000 title 1
BWVPHIKGXQBZPV-QKFDDRBGSA-N apelin Chemical compound NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N1[C@H](C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=2NC=NC=2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=2NC=NC=2)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CCSC)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(O)=O)CCC1 BWVPHIKGXQBZPV-QKFDDRBGSA-N 0.000 title 1
229920001184 polypeptide Polymers 0.000 abstract 3
102000004196 processed proteins & peptides Human genes 0.000 abstract 3
108090000765 processed proteins & peptides Proteins 0.000 abstract 3
206010007556 Cardiac failure acute Diseases 0.000 abstract 2
108091008803 APLNR Proteins 0.000 abstract 1
206010002027 Amyotrophy Diseases 0.000 abstract 1
201000001320 Atherosclerosis Diseases 0.000 abstract 1
206010003658 Atrial Fibrillation Diseases 0.000 abstract 1
206010059027 Brugada syndrome Diseases 0.000 abstract 1
206010007558 Cardiac failure chronic Diseases 0.000 abstract 1
208000031229 Cardiomyopathies Diseases 0.000 abstract 1
208000024172 Cardiovascular disease Diseases 0.000 abstract 1
206010016807 Fluid retention Diseases 0.000 abstract 1
206010020772 Hypertension Diseases 0.000 abstract 1
208000008589 Obesity Diseases 0.000 abstract 1
208000005764 Peripheral Arterial Disease Diseases 0.000 abstract 1
208000030831 Peripheral arterial occlusive disease Diseases 0.000 abstract 1
208000006011 Stroke Diseases 0.000 abstract 1
206010042496 Sunburn Diseases 0.000 abstract 1
208000032109 Transient ischaemic attack Diseases 0.000 abstract 1
208000030886 Traumatic Brain injury Diseases 0.000 abstract 1
208000027418 Wounds and injury Diseases 0.000 abstract 1
239000013543 active substance Substances 0.000 abstract 1
239000000556 agonist Substances 0.000 abstract 1
150000001408 amides Chemical class 0.000 abstract 1
206010003119 arrhythmia Diseases 0.000 abstract 1
230000006793 arrhythmia Effects 0.000 abstract 1
230000009787 cardiac fibrosis Effects 0.000 abstract 1
230000006378 damage Effects 0.000 abstract 1
206010012601 diabetes mellitus Diseases 0.000 abstract 1
150000002148 esters Chemical class 0.000 abstract 1
208000004104 gestational diabetes Diseases 0.000 abstract 1
208000014674 injury Diseases 0.000 abstract 1
230000000302 ischemic effect Effects 0.000 abstract 1
201000010901 lateral sclerosis Diseases 0.000 abstract 1
238000004519 manufacturing process Methods 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
208000005264 motor neuron disease Diseases 0.000 abstract 1
235000020824 obesity Nutrition 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
201000011461 pre-eclampsia Diseases 0.000 abstract 1
230000002265 prevention Effects 0.000 abstract 1
208000002815 pulmonary hypertension Diseases 0.000 abstract 1
208000037803 restenosis Diseases 0.000 abstract 1
230000001225 therapeutic effect Effects 0.000 abstract 1
201000010875 transient cerebral ischemia Diseases 0.000 abstract 1
230000009529 traumatic brain injury Effects 0.000 abstract 1
206010047302 ventricular tachycardia Diseases 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators; Tracheal tubes
- A61M16/08—Bellows; Connecting tubes ; Water traps; Patient circuits
- A61M16/0816—Joints or connectors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators; Tracheal tubes
- A61M16/0057—Pumps therefor
- A61M16/0066—Blowers or centrifugal pumps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators; Tracheal tubes
- A61M16/20—Valves specially adapted to medical respiratory devices
- A61M16/201—Controlled valves
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/50—Cyclic peptides containing at least one abnormal peptide link
- C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
- C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/50—Cyclic peptides containing at least one abnormal peptide link
- C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
- C07K7/60—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation occurring through the 4-amino group of 2,4-diamino-butanoic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators; Tracheal tubes
- A61M16/0003—Accessories therefor, e.g. sensors, vibrators, negative pressure
- A61M2016/0027—Accessories therefor, e.g. sensors, vibrators, negative pressure pressure meter
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators; Tracheal tubes
- A61M16/0003—Accessories therefor, e.g. sensors, vibrators, negative pressure
- A61M2016/003—Accessories therefor, e.g. sensors, vibrators, negative pressure with a flowmeter
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/35—Communication
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/50—General characteristics of the apparatus with microprocessors or computers
- A61M2205/502—User interfaces, e.g. screens or keyboards

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Hematology (AREA)
Biomedical Technology (AREA)
Pulmonology (AREA)
Diabetes (AREA)
Emergency Medicine (AREA)
Anesthesiology (AREA)
Immunology (AREA)
Epidemiology (AREA)
Gastroenterology & Hepatology (AREA)
Hospice & Palliative Care (AREA)
Obesity (AREA)
Endocrinology (AREA)
Dermatology (AREA)
Neurology (AREA)
Toxicology (AREA)
Child & Adolescent Psychology (AREA)
Urology & Nephrology (AREA)
Physical Education & Sports Medicine (AREA)

TNP2014000318A 2012-01-27 2014-07-23 Synthetic apelin mimetics for the treatment of heart failure TN2014000318A1 (en)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US201261591557P	2012-01-27	2012-01-27
US201261717760P	2012-10-24	2012-10-24
US201261731697P	2012-11-30	2012-11-30
PCT/IB2013/050666 WO2013111110A2 (fr)	2012-01-27	2013-01-25	Utilisation de mimétiques synthétiques de l'apeline pour le traitement de l'insuffisance cardiaque

Publications (1)

Publication Number	Publication Date
TN2014000318A1 true TN2014000318A1 (en)	2015-12-21

Family

ID=47997598

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TNP2014000318A TN2014000318A1 (en)	2012-01-27	2014-07-23	Synthetic apelin mimetics for the treatment of heart failure

Country Status (42)

Country	Link
US (3)	US8673848B2 (fr)
EP (1)	EP2807183B1 (fr)
JP (2)	JP6313222B2 (fr)
KR (2)	KR20200003229A (fr)
CN (1)	CN104220452B (fr)
AP (1)	AP2014007846A0 (fr)
AR (1)	AR089808A1 (fr)
AU (1)	AU2013213265C1 (fr)
BR (1)	BR112014018306A8 (fr)
CA (1)	CA2862240A1 (fr)
CL (1)	CL2014001994A1 (fr)
CO (1)	CO7020879A2 (fr)
CR (1)	CR20140364A (fr)
CU (1)	CU24266B1 (fr)
CY (1)	CY1120239T1 (fr)
DK (1)	DK2807183T3 (fr)
EA (1)	EA027853B1 (fr)
EC (1)	ECSP14016014A (fr)
ES (1)	ES2670832T3 (fr)
GT (1)	GT201400166A (fr)
HR (1)	HRP20180806T1 (fr)
HU (1)	HUE039137T2 (fr)
IL (1)	IL233792B (fr)
JO (1)	JO3380B1 (fr)
LT (1)	LT2807183T (fr)
MX (1)	MX351569B (fr)
MY (1)	MY172268A (fr)
NZ (1)	NZ627772A (fr)
PE (1)	PE20142194A1 (fr)
PH (1)	PH12014501701A1 (fr)
PL (1)	PL2807183T3 (fr)
PT (1)	PT2807183T (fr)
RS (1)	RS57200B1 (fr)
SG (1)	SG11201404369PA (fr)
SI (1)	SI2807183T1 (fr)
TN (1)	TN2014000318A1 (fr)
TR (1)	TR201807309T4 (fr)
TW (1)	TWI576356B (fr)
UA (1)	UA116196C2 (fr)
UY (1)	UY34593A (fr)
WO (1)	WO2013111110A2 (fr)
ZA (1)	ZA201405400B (fr)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8673848B2 (en) *	2012-01-27	2014-03-18	Novartis Ag	Synthetic apelin mimetics for the treatment of heart failure
UY35144A (es) *	2012-11-20	2014-06-30	Novartis Ag	Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
US8921307B2 (en) *	2012-11-20	2014-12-30	Novartis Ag	Synthetic linear apelin mimetics for the treatment of heart failure
CA2888445A1 (fr)	2012-11-30	2014-06-05	Novartis Ag	Procedes pour la fabrication de conjugues a partir de proteines contenant du disulfure
EP2935311B1 (fr) *	2012-12-20	2021-03-31	Amgen Inc.	Agonistes du récepteur apj et leurs utilisations
HK1220466A1 (zh) *	2013-03-14	2017-05-05	Regeneron Pharmaceuticals, Inc.	爱帕琳融合蛋白和其用途
US9908919B2 (en) *	2013-07-25	2018-03-06	Novartis Ag	Cyclic apelin derivatives for the treatment of heart failure
AU2014293386B2 (en) *	2013-07-25	2016-11-17	Novartis Ag	Cyclic polypeptides for the treatment of heart failure
US9683018B2 (en) *	2013-07-25	2017-06-20	Novartis Ag	Disulfide cyclic polypeptides for the treatment of heart failure
JP2016527249A (ja)	2013-07-25	2016-09-08	ノバルティスアーゲー	合成アペリンポリペプチドのバイオコンジュゲート
UA119247C2 (uk)	2013-09-06	2019-05-27	РОЙВЕНТ САЙЕНСИЗ ҐмбГ	Спіроциклічні сполуки як інгібітори триптофангідроксилази
BR112016011401A2 (pt)	2013-11-20	2017-09-26	Regeneron Pharma	moduladores de aplnr e utilizações dos mesmos
ES2729643T3 (es) *	2013-11-26	2019-11-05	Novartis Ag	Métodos para la conjugación de oxima con polipéptidos modificados con cetona
WO2015089137A1 (fr)	2013-12-11	2015-06-18	Karos Pharmaceuticals, Inc.	Acylguanidines comme inhibiteurs de la tryptophan hydroxylase
BR112016021835A8 (pt)	2014-03-25	2018-08-28	Lanthiopep Bv	análogo cíclico da apelina de fórmula geral x1-x2-x3-x4-x5-x6-x7-x8-x9-x10-x11-x12-x13-x14, composição farmacêutica, e método para proporcionar um análogo da apelina
GB201407532D0 (en) *	2014-04-29	2014-06-11	Univ Ulster	Apelin analogues
JP6721572B2 (ja)	2014-05-23	2020-07-15	ノバルティスアーゲー	ジスルフィド含有タンパク質からコンジュゲートを作製するための方法
US10588980B2 (en) *	2014-06-23	2020-03-17	Novartis Ag	Fatty acids and their use in conjugation to biomolecules
EP3851445A1 (fr)	2014-06-23	2021-07-21	Novartis AG	Modifications de protéines spécifiques à un site
WO2016109501A1 (fr)	2014-12-30	2016-07-07	Karos Pharmaceuticals, Inc.	Composés amides utilisés en tant qu'inhibiteurs de la tryptophane hydroxylase
BR112017014194A2 (pt)	2015-01-23	2018-01-09	Novartis Ag	conjugados de ácido graxo de apelina sintéticos com meia-vida melhorada
US9611201B2 (en)	2015-03-05	2017-04-04	Karos Pharmaceuticals, Inc.	Processes for preparing (R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethanol and 1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethanone
WO2016151018A1 (fr) *	2015-03-24	2016-09-29	INSERM (Institut National de la Santé et de la Recherche Médicale)	Méthode et composition pharmaceutique destinées à être utilisées dans le traitement du diabète
EA034776B1 (ru)	2015-05-20	2020-03-19	Эмджен Инк.	Триазоловые агонисты рецептора apj
WO2017140684A2 (fr)	2016-02-15	2017-08-24	INSERM (Institut National de la Santé et de la Recherche Médicale)	Procédés et compositions pharmaceutiques pour le traitement d'un dysfonctionnement cognitif postopératoire
US9988369B2 (en)	2016-05-03	2018-06-05	Amgen Inc.	Heterocyclic triazole compounds as agonists of the APJ receptor
CA3040517A1 (fr)	2016-10-19	2018-04-26	Avive, Inc.	Nouvelles formulations liposomales pegylees d'apeline pour le traitement de maladies liees au systeme cardiovasculaire
EP3541805B1 (fr)	2016-11-16	2020-10-14	Amgen Inc.	Triazoles substitués par hétéroaryle utilisés en tant qu'agonistes du récepteur apj
US11020395B2 (en)	2016-11-16	2021-06-01	Amgen Inc.	Cycloalkyl substituted triazole compounds as agonists of the APJ receptor
EP3541792B1 (fr)	2016-11-16	2020-12-23	Amgen Inc.	Composés de triazole furane utilisés en tant qu'agonistes du récepteur apj
US11191762B2 (en)	2016-11-16	2021-12-07	Amgen Inc.	Alkyl substituted triazole compounds as agonists of the APJ Receptor
WO2018093580A1 (fr)	2016-11-16	2018-05-24	Amgen Inc.	Composés de triazole pyridyle en tant qu'agonistes du récepteur apj
US10906890B2 (en)	2016-11-16	2021-02-02	Amgen Inc.	Triazole phenyl compounds as agonists of the APJ receptor
JOP20190245A1 (ar)	2017-04-20	2019-10-15	Novartis Ag	أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط
EP3681900A4 (fr)	2017-09-11	2021-09-08	Protagonist Therapeutics, Inc.	Peptides d'agoniste opioïde et leurs utilisations
US11149040B2 (en)	2017-11-03	2021-10-19	Amgen Inc.	Fused triazole agonists of the APJ receptor
WO2019213006A1 (fr)	2018-05-01	2019-11-07	Amgen Inc.	Pyrimidinones substituées en tant qu'agonistes du récepteur apj
EP3837276A4 (fr)	2018-08-16	2022-05-18	Isolere Bio, Inc.	Polypeptide génétiquement codé pour la capture et la purification par affinité de produits biologiques
KR20210102887A (ko)	2018-11-14	2021-08-20	알타반트 사이언시스 게엠베하	말초 세로토닌과 관련된 질병 또는 장애를 치료하기 위한 트립토판 하이드록실라제 1 (tph1)의 결정질 스피로사이클릭 화합물 억제제
CN112007027B (zh) *	2020-09-14	2022-07-15	长春金赛药业有限责任公司	含酯基芳香丙酰胺类化合物及其代谢产物在制备治疗心衰药物中的应用
CN119101143A (zh) *	2023-05-31	2024-12-10	浙江大学	一种G蛋白偏向的apelin-13多肽突变体及应用

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0846762A3 (fr)	1992-11-17	1998-09-23	Icos Corporation	Nouveau recepteur V31 du genre sept-transmembrane
US6555339B1 (en)	1997-04-14	2003-04-29	Arena Pharmaceuticals, Inc.	Non-endogenous, constitutively activated human protein-coupled receptors
AU1685499A (en)	1997-12-24	1999-07-19	Takeda Chemical Industries Ltd.	Polypeptide, their production and use
AU5759399A (en)	1998-09-25	2000-04-17	Takeda Chemical Industries Ltd.	Peptide derivative
DE69941337D1 (de)	1998-10-05	2009-10-08	Takeda Pharmaceutical	Verfahren zum eliminieren von n-terminalem methionin
US7045532B2 (en)	1999-04-30	2006-05-16	Millennium Pharmaceuticals, Inc.	ACE-2 modulating compounds and methods of use thereof
KR20020081466A (ko)	2000-03-23	2002-10-26	다케다 야쿠힌 고교 가부시키가이샤	펩티드 유도체
AU2001264937A1 (en)	2000-05-23	2001-12-03	Genaissance Pharmaceuticals, Inc.	Haplotypes of the agtrl1 gene
WO2003092581A2 (fr)	2001-07-16	2003-11-13	Hk Pharmaceuticals, Inc.	Composes de capture, recueils de ceux-ci et procedes d'analyse du proteome et compositions complexes
WO2003063892A1 (fr)	2002-01-29	2003-08-07	Takeda Chemical Industries, Ltd.	Utilisation d'apeline
DE602004027798D1 (de)	2003-03-12	2010-08-05	Univ Arizona State	Verfahren zur regulierung von angiogenese mit apelin-zusammensetzungen
US7947280B2 (en)	2003-05-22	2011-05-24	The Board Of Trustees Of The Leland Stanford Junior University	Apelin and uses thereof
WO2005029066A2 (fr)	2003-05-22	2005-03-31	Agilent Technologies, Inc.	Marqueurs de diagnostic et cibles pharmacologiques utilises dans l'insuffisance cardiaque, et reactifs connexes et leurs procedes d'utilisation
EP1520861A1 (fr)	2003-09-11	2005-04-06	Aventis Pharma Deutschland GmbH	Système d'essai pour l'identification des ligands du recepteur APJ
WO2005106493A1 (fr)	2004-04-30	2005-11-10	Bayer Healthcare Ag	Diagnostics et therapies pour maladies associees au recepteur de l'apeline couplee a une proteine g (apj)
EP1768951A4 (fr)	2004-06-17	2011-06-15	Musc Found For Res Dev	Acides amines non naturels
WO2006023893A2 (fr)	2004-08-23	2006-03-02	Arizona Board Of Regents On Behalf Of The University Of Arizona	Methodes de modulation de l'angiogenese et de l'apoptose, dans lesquelles sont utilisees des compositions a base d'apeline
JP2008013436A (ja)	2004-10-14	2008-01-24	Kanazawa Univ	血管形成促進剤
US20110097710A1 (en)	2004-10-26	2011-04-28	Macrae Calum A	Methods for detecting atrial fibrillation and related conditions
WO2006076736A2 (fr)	2005-01-14	2006-07-20	Arizona Board Of Regents On Behalf Of The University Of Arizona	Procedes de modulation d'angiogenese, de lymphangiogenese, et d'apoptose au moyen de compositions d'apeline
EP2330125A3 (fr)	2005-08-11	2012-12-12	Amylin Pharmaceuticals, Inc.	Polypeptides hybrides ayant des propriétés sélectionnables
US8673848B2 (en) *	2012-01-27	2014-03-18	Novartis Ag	Synthetic apelin mimetics for the treatment of heart failure
EP1876448A1 (fr)	2005-09-30	2008-01-09	DIGILAB BioVisioN GmbH	Méthodes et réactifs analytiques pour identifier des médicaments à l'aide de marqueurs biologiques sensibles aux thiazolidinediones
US7736346B2 (en)	2005-10-18	2010-06-15	Biocardia, Inc.	Bio-interventional therapeutic treatments for cardiovascular diseases
US20080031871A1 (en)	2006-02-21	2008-02-07	Allen Margaret L	Memory and learning impairments associated with disruption of Ephrin receptor A6 (EphA6) gene
EP2017355A4 (fr)	2006-04-25	2010-01-06	Univ Kyushu Nat Univ Corp	Gène associé à une maladie artérioscléreuse et utilisation de celui-ci
WO2009033819A2 (fr)	2007-09-11	2009-03-19	Mondobiotech Laboratories Ag	Utilisation d'un peptide en tant qu'agent thérapeutique
RU2010114020A (ru)	2007-09-11	2011-10-20	Мондобайотек Лабораториз Аг (Li)	Trap-14 в качестве терапевтического средства
WO2009075566A1 (fr)	2007-12-12	2009-06-18	Erasmus University Medical Center Rotterdam	Biomarqueurs pour maladie cardiovasculaire
US20110123534A1 (en)	2007-12-12	2011-05-26	Erasmus University Medical Center Rotterdam	Novel compounds for modulating neovascularisation and methods of treatment using these compounds
CN103396474A (zh)	2008-11-04	2013-11-20	安科治疗公司	Apj受体化合物
WO2010115874A1 (fr)	2009-04-07	2010-10-14	INSERM (Institut National de la Santé et de la Recherche Médicale)	Procédés pour le traitement et le diagnostic d'une hypertension artérielle pulmonaire
JP2013509874A (ja)	2009-11-04	2013-03-21	エラスムスユニバーシティメディカルセンターロッテルダム	新脈管形成を調節する為の新規化合物及びこれらの化合物を使用する処置方法
CA2797033C (fr)	2010-04-22	2021-10-19	Longevity Biotech, Inc.	Polypeptides tres actifs et procedes pour les preparer et les utiliser
TW201138808A (en)	2010-05-03	2011-11-16	Bristol Myers Squibb Co	Serum albumin binding molecules
RU2457216C1 (ru)	2010-12-21	2012-07-27	Федеральное государственное учреждение "Российский кардиологический научно-производственный комплекс" Министерства здравоохранения и социального развития Российской Федерации (ФГУ "РКНПК" Минздравсоцразвития России)	Додекапептиды, обладающие кардиопротекторными свойствами
WO2013106437A1 (fr)	2012-01-09	2013-07-18	Anchor Therapeutics, Inc.	Composés de récepteurs apj
AU2014293386B2 (en)	2013-07-25	2016-11-17	Novartis Ag	Cyclic polypeptides for the treatment of heart failure
US9908919B2 (en)	2013-07-25	2018-03-06	Novartis Ag	Cyclic apelin derivatives for the treatment of heart failure
US9683018B2 (en)	2013-07-25	2017-06-20	Novartis Ag	Disulfide cyclic polypeptides for the treatment of heart failure
JP2016527249A (ja)	2013-07-25	2016-09-08	ノバルティスアーゲー	合成アペリンポリペプチドのバイオコンジュゲート

2013
- 2013-01-23 US US13/747,621 patent/US8673848B2/en active Active
- 2013-01-24 JO JOP/2013/0027A patent/JO3380B1/ar active
- 2013-01-24 UY UY0001034593A patent/UY34593A/es not_active Application Discontinuation
- 2013-01-25 DK DK13711953.3T patent/DK2807183T3/en active
- 2013-01-25 EP EP13711953.3A patent/EP2807183B1/fr active Active
- 2013-01-25 UA UAA201408328A patent/UA116196C2/uk unknown
- 2013-01-25 KR KR1020197037887A patent/KR20200003229A/ko not_active Ceased
- 2013-01-25 AP AP2014007846A patent/AP2014007846A0/xx unknown
- 2013-01-25 TR TR2018/07309T patent/TR201807309T4/tr unknown
- 2013-01-25 EA EA201491433A patent/EA027853B1/ru not_active IP Right Cessation
- 2013-01-25 MX MX2014009085A patent/MX351569B/es active IP Right Grant
- 2013-01-25 CA CA2862240A patent/CA2862240A1/fr active Pending
- 2013-01-25 PE PE2014001176A patent/PE20142194A1/es active IP Right Grant
- 2013-01-25 SG SG11201404369PA patent/SG11201404369PA/en unknown
- 2013-01-25 SI SI201330999T patent/SI2807183T1/en unknown
- 2013-01-25 CN CN201380016261.6A patent/CN104220452B/zh not_active Expired - Fee Related
- 2013-01-25 AU AU2013213265A patent/AU2013213265C1/en not_active Ceased
- 2013-01-25 BR BR112014018306A patent/BR112014018306A8/pt not_active IP Right Cessation
- 2013-01-25 NZ NZ627772A patent/NZ627772A/en not_active IP Right Cessation
- 2013-01-25 PL PL13711953T patent/PL2807183T3/pl unknown
- 2013-01-25 RS RS20180546A patent/RS57200B1/sr unknown
- 2013-01-25 KR KR1020147023505A patent/KR102068370B1/ko not_active Expired - Fee Related
- 2013-01-25 WO PCT/IB2013/050666 patent/WO2013111110A2/fr not_active Ceased
- 2013-01-25 CU CUP2014000097A patent/CU24266B1/xx unknown
- 2013-01-25 HU HUE13711953A patent/HUE039137T2/hu unknown
- 2013-01-25 MY MYPI2014002154A patent/MY172268A/en unknown
- 2013-01-25 JP JP2014553847A patent/JP6313222B2/ja not_active Expired - Fee Related
- 2013-01-25 TW TW102103025A patent/TWI576356B/zh not_active IP Right Cessation
- 2013-01-25 LT LTEP13711953.3T patent/LT2807183T/lt unknown
- 2013-01-25 HR HRP20180806TT patent/HRP20180806T1/hr unknown
- 2013-01-25 ES ES13711953.3T patent/ES2670832T3/es active Active
- 2013-01-25 AR ARP130100228A patent/AR089808A1/es unknown
- 2013-01-25 PT PT137119533T patent/PT2807183T/pt unknown
2014
- 2014-01-28 US US14/165,680 patent/US9067971B2/en active Active
- 2014-07-22 ZA ZA2014/05400A patent/ZA201405400B/en unknown
- 2014-07-23 TN TNP2014000318A patent/TN2014000318A1/fr unknown
- 2014-07-24 IL IL233792A patent/IL233792B/en active IP Right Grant
- 2014-07-25 GT GT201400166A patent/GT201400166A/es unknown
- 2014-07-25 CL CL2014001994A patent/CL2014001994A1/es unknown
- 2014-07-25 PH PH12014501701A patent/PH12014501701A1/en unknown
- 2014-07-28 CR CR20140364A patent/CR20140364A/es unknown
- 2014-07-31 CO CO14167109A patent/CO7020879A2/es unknown
- 2014-08-27 EC ECIEPI201416014A patent/ECSP14016014A/es unknown
2015
- 2015-05-18 US US14/714,914 patent/US9982017B2/en active Active
2017
- 2017-10-06 JP JP2017195815A patent/JP6595553B2/ja not_active Expired - Fee Related
2018
- 2018-05-24 CY CY20181100556T patent/CY1120239T1/el unknown

Also Published As

Publication number	Publication date
JP2015506370A (ja)	2015-03-02
US9982017B2 (en)	2018-05-29
EA027853B1 (ru)	2017-09-29
CN104220452B (zh)	2018-01-26
HRP20180806T1 (hr)	2018-06-29
EP2807183A2 (fr)	2014-12-03
IL233792A0 (en)	2014-09-30
KR20200003229A (ko)	2020-01-08
AU2013213265A1 (en)	2014-09-18
RS57200B1 (sr)	2018-07-31
JO3380B1 (ar)	2019-03-13
MY172268A (en)	2019-11-20
UY34593A (es)	2013-09-02
AP2014007846A0 (en)	2014-08-31
AR089808A1 (es)	2014-09-17
JP6595553B2 (ja)	2019-10-23
HK1200470A1 (en)	2015-08-07
EP2807183B1 (fr)	2018-02-28
US20140142022A1 (en)	2014-05-22
AU2013213265C1 (en)	2016-09-29
CR20140364A (es)	2014-11-17
KR20140117603A (ko)	2014-10-07
TWI576356B (zh)	2017-04-01
CL2014001994A1 (es)	2014-11-03
TW201335190A (zh)	2013-09-01
WO2013111110A2 (fr)	2013-08-01
MX351569B (es)	2017-10-19
PT2807183T (pt)	2018-05-29
PL2807183T3 (pl)	2018-08-31
TR201807309T4 (tr)	2018-06-21
IL233792B (en)	2018-04-30
SI2807183T1 (en)	2018-05-31
PH12014501701A1 (en)	2014-10-13
UA116196C2 (uk)	2018-02-26
GT201400166A (es)	2015-10-15
ES2670832T3 (es)	2018-06-01
HUE039137T2 (hu)	2018-12-28
LT2807183T (lt)	2018-05-10
KR102068370B1 (ko)	2020-01-21
WO2013111110A3 (fr)	2013-10-31
US20150252076A1 (en)	2015-09-10
JP2018048157A (ja)	2018-03-29
NZ627772A (en)	2015-11-27
CN104220452A (zh)	2014-12-17
BR112014018306A2 (fr)	2017-06-20
AU2013213265B2 (en)	2016-05-26
EA201491433A1 (ru)	2014-12-30
DK2807183T3 (en)	2018-06-06
ECSP14016014A (es)	2015-11-30
US20130196899A1 (en)	2013-08-01
JP6313222B2 (ja)	2018-04-18
BR112014018306A8 (pt)	2017-07-11
CO7020879A2 (es)	2014-08-11
MX2014009085A (es)	2014-08-27
CA2862240A1 (fr)	2013-08-01
CU20140097A7 (es)	2015-03-30
SG11201404369PA (en)	2014-08-28
ZA201405400B (en)	2016-08-31
PE20142194A1 (es)	2014-12-21
US8673848B2 (en)	2014-03-18
CU24266B1 (es)	2017-07-04
CY1120239T1 (el)	2019-07-10
US9067971B2 (en)	2015-06-30

Publication	Publication Date	Title
TN2014000318A1 (en)	2015-12-21	Synthetic apelin mimetics for the treatment of heart failure
PH12016500103A1 (en)	2016-04-18	Bioconjugates of synthetic apelin polypeptides
PH12016500104A1 (en)	2016-04-18	Cyclic polypeptides for the treatment of heart failure
Mascolo et al.	2020	Angiotensin II and angiotensin 1–7: which is their role in atrial fibrillation?
JP2018048157A5 (fr)	2018-05-31
RU2020123679A (ru)	2022-01-17	Композиции и способы лечения и/или предотвращения сердечно-сосудистого заболевания
JP2016531110A5 (fr)	2017-08-31
CO2019013768A2 (es)	2020-04-01	Compuestos de mic-1 y usos de estos
PH12017501112A1 (en)	2017-11-27	Synthetic apelin fatty acid conjugates with improved half-life
JP2018507187A5 (fr)	2019-02-21
TN2016000029A1 (en)	2017-07-05	Bioconjugates of synthetic apelin polypeptides
MA38864A1 (fr)	2017-11-30	Polypeptides cycliques pour le traitement de l'insuffisance cardiaque
Aizawa et al.	2007	Atrial Fibrillation Revisited—With a Special Reference to Primary Prevention—
Muhammad	2013	Efficacy Evaluation of Pharmaceutical Optimized Ramipril 1.25 mg (F-4) with Essential Hypertension
Li et al.	2013	GW24-e1365 Effects of renal sympathetic denervation on ventricular remodelling in canine
LV14266A (lv)	2011-01-20	Jauna nikot&imacr;nsk&amacr;bes un meldonija terapeitiska kombin&amacr;cija
TH89523B (th)	2008-04-30	สารผสมสำหรับลดการเกิดขึ้นของภาวะหัวใจเต้นปกติที่ถูกชักนำด้วยยา